BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 11693316)

  • 1. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
    Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
    Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
    J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
    Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
    Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
    Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
    Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
    J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
    Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
    J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers in Barrett's esophagus.
    Reid BJ; Blount PL; Rabinovitch PS
    Gastrointest Endosc Clin N Am; 2003 Apr; 13(2):369-97. PubMed ID: 12916666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.
    Reid BJ; Levine DS; Longton G; Blount PL; Rabinovitch PS
    Am J Gastroenterol; 2000 Jul; 95(7):1669-76. PubMed ID: 10925966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barrett's esophagus: a model of human neoplastic progression.
    Neshat K; Sanchez CA; Galipeau PC; Cowan DS; Ramel S; Levine DS; Reid BJ
    Cold Spring Harb Symp Quant Biol; 1994; 59():577-83. PubMed ID: 7587115
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.
    Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):745-52. PubMed ID: 12163328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma.
    Suspiro A; Pereira AD; Afonso A; Albuquerque C; Chaves P; Soares J; Leitão CN
    Am J Gastroenterol; 2003 Apr; 98(4):728-34. PubMed ID: 12738448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
    Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
    PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.
    Reid BJ; Blount PL; Rubin CE; Levine DS; Haggitt RC; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1212-9. PubMed ID: 1551528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
    Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
    Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.
    Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
    Gastroenterology; 1987 Jul; 93(1):1-11. PubMed ID: 3582897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.
    Galipeau PC; Cowan DS; Sanchez CA; Barrett MT; Emond MJ; Levine DS; Rabinovitch PS; Reid BJ
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7081-4. PubMed ID: 8692948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.
    Li X; Galipeau PC; Sanchez CA; Blount PL; Maley CC; Arnaudo J; Peiffer DA; Pokholok D; Gunderson KL; Reid BJ
    Cancer Prev Res (Phila); 2008 Nov; 1(6):413-23. PubMed ID: 19138988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.